MONOCLONAL-ANTIBODIES AGAINST CD54 (ICAM-1) AND CD11A (LFA-1) PREVENT AND INHIBIT ENDOTOXIN-INDUCED UVEITIS

We studied the effect of monoclonal antibodies (mAbs) against CD54 (intercellular adhesion molecule-1; ICAM-1) and CD11a (lymphocyte function-associated antigen-1; LFA-1) on the prevention and treatment of endotoxin-induced uveitis (EIU). When treated at the time of endotoxin injection the mean number of inflammatory cells infiltrating the eye+/-S.E.M. on histologic sections was 469.2+/-51.9 for controls, 13.8+/-2.6 for rats receiving anti-ICAM-1 mAb (P<0.0001), and 195.8+/-48.8 for rats receiving anti-LFA-1 mAb (P=0.0003). When treated after the start of inflammatory disease, the mean number of infiltrating inflammatory cells+/-S.E.M. was 273.0+/-30.7 for controls, 6.4+/-1.7 for rats receiving anti-ICAM-1 mAb (P<0.0001), and 54.2+/-7.6 for rats receiving anti-LFA-1 mAb (P<0.0001). The mean number of cells per milliliter of aqueous humor+/-S.E.M. was 1867.6+/-321.8 for controls, 21.7+/-5.3 for rats receiving anti-ICAM-1 mAb (P<0.0001), and 295.1+/-71.2 for rats receiving anti-LFA-1 mAb (P<0.0001). MAbs against ICAM-1 and LFA-1 significantly inhibited the development of EIU and were effective in treating clinically evident ocular inflammatory disease.